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A comparison of clofarabine with ara-C, each in combination
with daunorubicin as induction treatment in older patients
with acute myeloid leukaemia
AK Burnett1, NH Russell2, RK Hills3, J Kell4, OJ Nielsen5, M Dennis6, P Cahalin7, C Pocock8, S Ali9, S Burns3, S Freeman10, D Milligan11
and RE Clark12 on behalf of the UK NCRI AML Study Group
The study was designed to compare clofarabine plus daunorubicin vs daunorubicin/ara-C in older patients with acute myeloid
leukaemia (AML) or high-risk myelodysplastic syndrome (MDS). Eight hundred and six untreated patients in the UK NCRI AML16 trial
with AML/high-risk MDS (median age, 67 years; range 56–84) and normal serum creatinine were randomised to two courses of
induction chemotherapy with either daunorubicin/ara-C (DA) or daunorubicin/clofarabine (DClo). Patients were also included in
additional randomisations; ± one dose of gemtuzumab ozogamicin in course 1; 2v3 courses and ± azacitidine maintenance. The
primary end point was overall survival. The overall response rate was 69% (complete remission (CR) 60%; CRi 9%), with no
difference between DA (71%) and DClo (66%). There was no difference in 30-/60-day mortality or toxicity: signiﬁcantly more
supportive care was required in the DA arm even though platelet and neutrophil recovery was signiﬁcantly slower with DClo. There
were no differences in cumulative incidence of relapse (74% vs 68%; hazard ratio (HR) 0.93 (0.77–1.14), P= 0.5); survival from relapse
(7% vs 9%; HR 0.96 (0.77–1.19), P= 0.7); relapse-free (31% vs 32%; HR 1.02 (0.83–1.24), P= 0.9) or overall survival (23% vs 22%; HR
1.08 (0.93–1.26), P= 0.3). Clofarabine 20 mg/m2 given for 5 days with daunorubicin is not superior to ara-C+daunorubicin as
induction for older patients with AML/high-risk MDS.
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INTRODUCTION
Although progress has been made with intensive treatments for
younger patients with acute myeloid leukaemia (AML),1,2 improve-
ment in older patients given the same schedules is much more
modest.3,4 This is usually attributed to the higher frequency of
disease with adverse biological features than in younger patients,
which responds less frequently and for shorter duration. The other
difference is that co-morbidities accumulate with age, whether
apparent or not, and the tolerance to intensive therapy is poorer
with a higher risk of induction mortality and reduced ability to
deliver the total planned treatment.5,6 More effective treatments
are therefore required, which are both more efﬁcacious and also
have better tolerability.
Clofarabine (2-chloro-2′-ﬂuoro-deoxy-9-ß-D-arabinofuranosyla-
denine) is a novel nucleoside analogue which was developed in
a large screening programme to ﬁnd new therapeutics which
incorporate the beneﬁcial properties of this class of drugs. In
particular, ﬂudarabine and cladribine are active as single agents in
AML but at dose levels associated with prohibitive toxicity, which
is due to the cleavage product 2-ﬂuoroadenine being converted
to toxic 2-ﬂuoroadenosine.7,8 Clofarabine is the result of a
programme of development exploring a series of chemical
modiﬁcations to minimise cleavage while retaining activity.9 It
depends on membrane nucleoside transporters for cell entry and
is sequentially phosphorylated in deoxycytidine kinase-dependent
steps to the triphosphate, the active form of which is retained
within cells for longer than other purine nucleoside analogues.
Following initial studies in relapsed disease which conﬁrmed its
activity,10 two reports incorporating three un-randomised
studies11,12 assessed the front-line activity using lower doses in
older patients who were considered unﬁt for intensive therapy.
These studies were consistent in delivering complete remission to
more than 40% of patients, and of interest this responsiveness did
not seem to be limited by age or cytogenetic risk group. Given its
favourable toxicity proﬁle, potential for oral administration and
similarity to ﬂudarabine, it became a potential candidate novel
therapy for the older patient. These trials did not establish the
duration of response. In one of these pilot trials no renal function
restriction was required, hence a dose level of 20 mg/m2 was
tested in a small number of patients against the conventional
30 mg/m2 dose and produced a similar efﬁcacy, but with a more
favourable toxicity proﬁle.11
On this basis we conducted a randomised trial in patients not
considered suitable for intensive therapy, comparing clofarabine
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at a daily dose of 20 mg/m2 for ﬁve consecutive days, with low-
dose ara-C (20 mg b.i.d. for 10 days).13 The remission rate was
doubled by clofarabine, but overall survival (OS) was not improved
because the survival of patients who failed to achieve complete
remission on the clofarabine arm was worse, and when patients
relapsed from a clofarabine-induced remission their survival was
poorer than for those who relapsed from low-dose ara-C. In the
current study as part of the United Kingdom National Cancer
Research Institute (NCRI) AML16 Trial (ISRCTN 11036523), we
wished to test clofarabine combined with daunorubicin vs ara-C
combined with daunorubicin as induction therapy for older
patients for whom conventional therapy was indicated.
PATIENTS AND METHODS
The protocol was designed for older patients, generally age 460 years,
who did not have blast transformation of chronic myeloid leukemia or
acute promyelocytic leukemia. Patients with high-risk myelodysplastic
syndrome (MDS), which was deﬁned as410% marrow blasts at diagnosis,
were eligible. A small number of patients aged o60 years, who were not
considered suitable for the concurrent AML15 trial for younger patients
(which included high-dose ara-C), were included. Secondary AML was
deﬁned as resulting from either antecedent haematologic disorder or prior
chemotherapy treatment for a non-haematological malignancy. The trial
was conducted in accordance with the Declaration of Helsinki; it was
sponsored by Cardiff University and was approved by Wales REC 3. All
patients provided written informed consent to random treatment assign-
ment. Patients were randomly assigned between two courses of
chemotherapy comprising daunorubicin/ara-C or daunorubicin/clofara-
bine. To be eligible for randomisation assignment, patients were required
to have serum creatinine within local normal limits.
The treatment plan is set out in Figure 1 and the number of patients in
the DClo vs DA induction randomisation who entered these randomisa-
tions is included in Table 1.
The median age of the patients was 67 years (range 56–84), 59% were
male, 72% had de novo AML, 17% secondary AML and 11% had high-risk
MDS. Six percent had a WHO performance score of 42; 14% had an FLT3
mutation and 20% had an NPM1c mutation. The cytogenetic risk category
as previously deﬁned14 was 4% favourable, 73% intermediate and 23%
adverse risk. Using the validated Wheatley Risk Score,15 which is based on
age, cytogenetics, presenting white count, presence of secondary disease
and performance status, three risk groups were deﬁned (30% were good,
34% standard and 36% poor) with survival at 2 years of 29, 17 and 9%,
respectively.
Statistical methods
The primary outcome measure for the trial was OS. The study was powered
to detect a difference of 10% in absolute 2-year survival from 25 to 35%
(equivalent to hazard ratio (HR) of 0.76), with 90% power at Po0.05. This
required a minimum of 552 deaths, and at least 800 patients had to be
recruited. Secondary end points were achievement of complete remission
(CR), CR with incomplete peripheral count recovery (CRi), relapse-free
survival, relapse and death in remission (the last three for patients
achieving either CR or CRi), together with resource use and toxicity
(haematologic recovery times and non-haematologic toxicity scored using
National Cancer Institute Common Toxicity Criteria, Version 3).
All end points were deﬁned according to the revised International
Working Group criteria,16 including the use of competing-risks methodol-
ogy to estimate cumulative incidence of relapse (CIR), with the exception
that in the protocol as written, the deﬁnition of CR did not require count
recovery; however, because these data were routinely available, in this
report, we divided patients into those who achieved CR by International
Working Group criteria and those who instead achieved CRi. On the
recommendation of the Data Monitoring and Ethics Committee, the trial
was analyzed once a minimum of 1-year follow-up was available and a
minimum of 552 deaths had been observed. Follow-up was complete for
98% of patients to 1 March 2015; follow-up for patients was censored on
the date they were last known to be alive. Median follow-up was calculated
using reverse censoring. Survival for patients withdrawing from follow-up
was censored on the date of withdrawal; one patient withdrew consent in
this cohort. All analyses were performed by intention to treat; time-to-
event data were summarised using Kaplan–Meier or cumulative incidence
estimates and analyzed using the log-rank test, with the Mantel–Haenszel
test used for dichotomous outcomes such as remission. Resource usage
and toxicity data were compared using the Wilcoxon rank-sum test. As per
Figure 1. Trial design of AML16 (acute myeloid leukemia; intensive arm) from 2006 to 2009. C, course; CR, complete remission; PR, partial
remission; Rx, treatment.
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the statistical analysis plan, analyses of outcome were performed, stratiﬁed
by the randomisation stratiﬁcation parameters (age, WBC, WHO
performance status, type of disease (de novo, secondary, high-risk MDS),
and entry into the other induction randomisation) as well as the cytogenetic
group (deﬁned using the MRC classiﬁcation14) and other potentially
important factors, such as FLT3-ITD and NPM1 mutations.
Such stratiﬁed analyses are presented in Forest plots using standard meta-
analytic techniques, with suitable tests for interaction (trend or hetero-
geneity) performed. Because the trial was designed factorially, later
randomisations did not affect the results of the induction randomi-
sations, because allocation was stratiﬁed for treatment received in induction.
The results of the gemtuzumab ozogamicin randomisation have already
been reported in full,17 and the consolidation and maintenance
randomisations will be reported elsewhere.
Minimal residual disease assessment by ﬂow cytometry, with a
sensitivity of 1 × 104, was undertaken in 135 of 410 randomised patients
who were in morphological remission after the ﬁrst induction course. The
methods have been described in detail elsewhere.18 Samples of bone
marrow were collected after recovery from 135 patients in CR post course
and 154 patients in CR post course 2.
RESULTS
Between August 2006 and December 2008, 806 untreated patients
from 124 centres in the UK, Denmark and New Zealand were
randomised to receive either two induction courses of DClo:
Table 1. Patient characteristics by arm
Characteristics DA (n=402) DClo (n= 404)
Age
o60 8 8
60–64 115 116
65–69 168 168
70–74 89 89
75+ 22 23
Median (range) 67 (56–84) 67 (56–80)
Sex
Female 172 154
Male 230 250
Diagnosis
De novo 289 290
Secondary 69 71
High-risk MDS 44 43
WBC (×109/l)
o10 249 251
10–49.9 112 111
50–99.9 23 25
100+ 18 17
Median 4.1 (0.2–266.0) 5.2 (0.2–336.7)
Performance status
WHO PS 0 250 250
WHO PS 1 130 130
WHO PS 2 13 16
WHO PS 3,4 9 8
Cytogenetics
Favourable 15 9
Intermediate 229 228
Adverse 67 77
Unknown 91 90
Wheatley group
Good 129 112
Standard 137 141
Poor 136 151
FLT3-ITD
Wild type 101 97
Mutant 14 18
Unknown 287 289
NPM1
Wild type 92 80
Mutant 19 23
Unknown 291 301
GO induction
GO 171 172
No GO 170 170
Not randomised 61 64
Consolidation
2 courses 68 63
3 courses 70 62
Not randomised 264 279
Maintenance
Maintenance 67 70
No maintenance 70 67
Not randomised 265 267
Abbreviation: GO, gemtuzumab ozogamicin.
Figure 2. CONSORT diagram.
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daunorubicin 50 mg/m2 on days 1, 3 and 5 combined with
clofarabine 20 mg/m2 on days 1–5, or two courses of DA:
daunorubicin 50 mg/m2 combined with ara-C 100 mg/m2 b.i.d.
days 1–10 in course 1 and days 1–8 in course 2. Fifty-nine patients
were excluded from the randomisation based on renal criteria and
were allocated to the daunorubicin/ara-C induction, but were
eligible to be considered for the other trial randomisations.
The other interventions included gemtuzumab ozogamicin
3 mg/m2 or not in course 1. Patients who achieved a complete
remission (CR), complete remission with incomplete platelet
recover (CRi), or a partial remission (o15% blasts in the bone
marrow) in response to course 1 and were in CR after 2 induction
courses were eligible to be randomised to have a single
consolidation course (daunorubicin 50 mg/m2 on days 1 and 3
combined with ara-C 100 mg/m2 b.i.d. on days 1–5) or no
consolidation, and to receive, or not receive, maintenance
treatment with azacitidine 75 mg/m2 for 5 days every 6 weeks
for 12 months (9 courses). The disposition of patients is shown in
the CONSORT diagram (Figure 2).
The compliance with the allocated treatment was 98% and the
overall response rate (CR+CRi) was 68% and survival at 5 years is 15%.
Remission induction
The results of induction treatment are summarised in Table 2.
Overall, 61% of patients entered CR, and an additional 7%
achieved marrow remission with incomplete recovery of periph-
eral blood counts (i.e. CRi). Remission (CR or CRi) was recorded
after course one in 51% of patients; after course two, in an
additional 14%. In 3% of patients remission took more than two
courses. There was a trend for a superior CR rate in the DA patients
64% vs DClo, 58% (OR 1.30 (0.98–1.73), P= 0.07), and an additional
6 and 8%, respectively, achieved a CRi; thus, the overall response
rate was 71% vs 66% (HR 1.26 (0.94–1.70), P= 0.12). The induction
deaths were not different (11% vs 11%; OR 0.99 (0.64–1.55),
P= 1.0) and 30-day (9% vs 8%) and 60-day (15% vs 14%)
mortalities were not signiﬁcantly different (Table 2).
In the samples in morphological remission which were assessed
for MRD, the positivity after course 1 in the DA patients was 52%
and in the DClo patients was 54% (P= 0.9). After course 2 the MRD
positivity was 34 and 39%, respectively (P= 0.5). There was no
suggestion of a beneﬁt of any particular demographic or
cytogenetic subgroup, whether an FLT3 or NPM1c mutation as
present or whether the patient received gemtuzumab ozogamicin
or not (Supplementary Figure S1).
Toxicity
With the exception of diarrhoea (12% with DA in course 1) and
nausea (10% with DClo in course 1), no grade 3 or 4 toxicity was
recorded in more than 10% of patients on either treatment arm
during either induction courses (Table 3). The median day of
recovery of neutrophils and platelets measured from the end of
Table 2. Outcomes by treatment arms—all estimates are at 5 years except if stated otherwise
DA (%) DClo (%) HR/OR, 95% CI P-value
CR 64 58 1.30 (0.98–1.73) 0.07
CRi 6 8
ORR (CR+CRi) 71 66 1.26 (0.94–1.70) 0.12
Resistant disease 18 24 1.36 (0.97–1.91) 0.08
Induction death 11 11 0.99 (0.64–1.55) 1.0
30-day mortality 9 8 0.98 (0.61–1.57) 0.9
60-day mortality 15 14 0.96 (0.67–1.39) 0.8
Overall survival 14 15 1.04 (0.90–1.21) 0.6
Relapse-free survival 14 15 0.99 (0.83–1.19) 0.9
Cumulative incidence of relapse 78 72 0.93 (0.77–1.13) 0.5
Cumulative incidence of death in CR 8 13 1.47 (0.89–2.43) 0.13
Survival post CR 20 23 0.96 (0.80–1.16) 0.7
Survival post relapse 4 8 0.92 (0.75–1.13) 0.4
Table 3. Toxicity outcomes—tests are by Wilcoxon rank-sum test
except for *(log-rank test)
Toxicity DA DClo P-value
%
grade
3–4
Mean
grade
%
grade
3–4
Mean
grade
Course 1
Nausea 5% 0.8 10% 1.0 0.01
Oral 3% 0.7 2% 0.7 0.4
Diarrhoea 12% 1.1 8% 1.0 0.12
Cardiac 7% 0.4 5% 0.3 0.3
Liver AST 6% 0.6 6% 0.5 0.6
Liver ALT 4% 0.6 6% 0.7 0.3
Bilirubin 7% 0.8 5% 0.7 0.04
Median days to
neutrophil recovery
20 24 o0.0001*
Median days to
platelet recovery
21 24 o0.0001*
Mean blood units 11.0 9.5 0.0002
Mean platelet units 12.9 9.8 o0.0001
Mean days
antibiotics
19.7 16.7 o0.0001
Mean
hospitalisation days
33.8 31.4 o0.0001
Course 2
Nausea 4% 0.7 7% 0.9 0.004
Oral 1% 0.4 1% 0.4 0.9
Diarrhoea 4% 0.6 9% 0.7 0.19
Cardiac 2% 0.1 2% 0.2 0.7
Liver AST 1% 0.2 4% 0.4 0.06
Liver ALT 3% 0.4 2% 0.6 0.004
Bilirubin 3% 0.5 5% 0.4 0.4
Median days to
neutrophil recovery
20 21 0.2*
Median days to
platelet recovery
25 24 0.3*
Mean blood units 6.3 6.4 0.9
Mean platelet units 6.0 5.7 0.03
Mean days
antibiotics
9.4 9.6 0.6
Mean
hospitalisation days
25.0 23.4 0.01
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the course was signiﬁcantly longer in the DClo arm (neutrophils
20 vs 24 days, Po0.0001; platelets 21 vs 24 days, Po0.0001).
Signiﬁcantly more red cell and platelet transfusions, days on
antibiotic and days in hospital were required after course 1 in the
DA arm (Table 3). There was little difference in transfusion
requirement after course 2.
Relapse
The ﬁve-year cumulative incidence of relapse (Figure 3a) was 75%
(DA 78% vs DClo 72%; HR 0.93 (0.77–1.13), P= 0.5). In the
exploratory analysis of subgroups no differences were found
(Supplementary Figure S2). The respective survival from relapse
(Figure 3b) was also not different (4% vs 8%; HR 0.92 (0.75–1.13),
P= 0.4).
Relapse-free survival
Death without relapse was nonsigniﬁcantly increased in the DClo
arm (8% vs 13%; HR 1.47 (0.89–2.43), P= 0.13). Taken together with
the nonsigniﬁcant difference in relapse, no difference was found
between the arms in relapse-free survival (14% vs 15%) (HR 0.99
(0.83–1.19), P= 0.9; Figure 3c) or survival from CR (20% vs 23%; HR
0.96 (0.80–1.16), P= 0.7; Figure 3d).
Overall survival
No difference was found in survival (DA 15%, DClo 14%; HR 0.96
(0.67–1.39), P= 0.8; Figure 4a) either overall or within exploratory
subgroups (Supplementary Figure S3). In particular, there was no
signiﬁcant interaction with any other treatments. There were no
obvious differences between the causes of the 355 deaths on the
DA arm vs the 347 on the DClo arm with about half in each case
being due to refractory or recurrent disease (Figure 4b).
DISCUSSION
The inability to develop an improved induction regimen for older
patients with AML is a major issue, but it is also true for younger
patients, such that the combination of daunorubicin and ara-C
remains the standard of care. Variations in dose and scheduling of
the two drugs have been explored in many studies in patients of
all ages, but dose escalation options are limited in older
patients.19–23 The general use of the higher dose (90 mg/m2) of
daunorubicin was not of overall beneﬁt in older patients although
it did improve outcome in the subset aged 60–65 years when
compared with a 45 mg/m2 dose level.20 Gemtuzumab ozogami-
cin in this NCRI AML16 trial when added to induction course 1 in a
small dose of 3 mg/m2 produced an OS beneﬁt, as it did in the
French ALFA study in patients aged 50–70 years using a different
schedule.17,24 In our AML15 trial, which was intended for younger
patients (o60 years), we observed a powerful antileukaemic
effect when using the FLAG-Ida (ﬂudarabine/ara-C/G-CSF/Idarubi-
cin) combination,25 which is now being prospectively assessed in
older patients.
Alternative nucleoside analogues have recently been explored
in AML with mixed results. The addition of cladrabine26 to
standard DA treatment appears promising particularly in younger
patients with adverse risk cytogenetics. Single-agent sapacitabine
in older unﬁt patients was not beneﬁcial,27 but other studies in
combination are underway or yet to be reported. Clofarabine as
monotherapy has been rather ambitiously compared with
standard 3+7 daunorubicin, but was unsuccessful.28 An obvious
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setting in which to assess clofarabine was as a replacement for
ara-C in combination with an anthracycline. This had a number of
attractions. First it had been developed as a 5-day schedule
compared with the need for 7 or 10 days of ara-C. Second, in the
preliminary studies it appeared to be equally effective in adverse
risk patients who of course are well represented in an older
population. Third, it had the prospect of being taken orally.
In the initial studies in relapsed disease undertaken by the MD
Anderson group,10 the dose used was 40 mg/m2. However when
initially targeting the older unﬁt patient population we felt that a
lower dose of 30 mg/m2 would be wise. Even at this dose in
unselected older patients some renal toxicity was observed, which
required more rigorous entry criteria with respect to renal
function. We also explored a lower daily dose of 20 mg/m2,11
which was found to be well tolerated, with less renal and hepatic
biochemical abnormalities being seen, without any loss of efﬁcacy.
This dose level was then explored as monotherapy in older
patients judged to be unﬁt for conventional therapy.11,12 After a
brief safety assessment of the combination with daunorubicin in
older patients considered suitable candidates for intensive
therapy,29 the randomised comparison was initiated. The results
presented here provide no evidence overall, or in any subgroup,
to suggest that ara-C should be replaced by clofarabine, at least at
the 20 mg/m2 daily dose. Taken together, and acknowledging the
issue of exploring higher doses in combination, the clinical
experience so far does not suggest that clofarabine should
displace existing treatments. New treatment options such as
addition of inhibitors of FLT3, IDH1 and IDH2 hold promise, but
also challenges because of the lower frequency of speciﬁc
mutations in older patients. Of recent interest is the liposomal
formulation of the combination of daunorubicin and ara-C
(CPX-351) which is a novel way of delivering therapy and has
proved to be more effective in older patients with secondary
AML.30,31
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Patel, Dr R Kaczmarski; Hull Royal Inﬁrmary: Dr C Carter, Dr S Ali; Ipswich
Hospital: Dr J A Ademokun, Dr N J Dodd; James Paget Hospital: Dr Cesar Gomez,
Dr Shalal Sadullah; Kent & Canterbury Hospital: Dr C F E Pocock, Dr F Zwaan,
Dr K Saied, Dr V Ratnayake; Kettering General Hospital: Dr M Lyttleton, Dr Mark
Kwan; Kingston Hospital: Dr H Sykes, Dr Z Abboudi; Leeds General Inﬁrmary:
Dr D T Bowen, Dr Rod Johnson; Leicester Royal Inﬁrmary: Dr A E Hunter; Lincoln
County Hospital: Dr K Saravanamuttu; Maidstone District General Hospital:
Dr Richard F Gale, Dr Saad Rassam; Manchester Royal Inﬁrmary: Dr G S Lucas,
Dr J Burthem, Professor J A Liu Yin; Medway Maritime Hospital: Dr Ayed Eden,
Dr Maadh Aldouri, Dr V E Andrews; Monklands Hospital: Dr J A Murphy,
Dr Lindsay Mitchell; Musgrove Park Hospital: Dr S Bolam; New Cross Hospital:
Dr A Jacob, Dr A MacWhannell, Dr S Basu, Dr Sunil Handa; Ninewells Hospital:
Dr D Meiklejohn, Dr Duncan Ian Gowans, Dr Keith Gelly, Dr S Tauro; Norfolk
& Norwich University Hospital: Dr Matthew Lawes; North Manchester General
Hospital: Dr David Osbourne, Dr Hayley Greenﬁeld; North Staffordshire Hospital:
Dr A Stewart, Dr D Chandra, Dr David Allotey, Dr R C Chasty; Northwick Park
Hospital: Dr N Panoskaltsis; Nottingham University Hospitals NHS Trust—City
Hospital Campus: Dr E Das-Gupta, Dr J L Byrne, Professor N H Russell; Odense
University Hospital: Dr Lone Friis; Pilgrim Hospital: Dr Ara Kiorkian,
Dr K Saravanamuttu, Dr SS Sobolewski, Dr V Tringham; Pinderﬁelds General
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Figure 4. Overall survival: (a) survival by arm and (b) histogram of
causes of death.
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Hospital: Dr D Wright, Dr John Ashcroft, Dr K Patil, Dr Paul Moreton;
Poole General Hospital: Dr AJ Bell, Dr F Jack; Princess Royal University Hospital:
Dr A Lakhani, Dr B Vadher, Dr C De Lord; Queen Alexandra Hospital:
Dr M Ganczakowski, Dr R Corser; Queen Elizabeth Hospital (Kings Lynn):
Dr AJ Keidan, Dr P Coates; Queen Elizabeth Hospital Birmingham: Dr JA Murray,
Professor Charles F Craddock; Queen's Hospital, Romford: Dr A Brownell,
Dr I Grant, Dr Jane Stevens; Raigmore Hospital: Dr C Lush, Dr P Forsyth,
Dr William Murray; Rigshospitalet University Hospital: Dr Jesper Jurlander,
Dr Lars Kjeldsen, Dr Ole Weis Bjerrum, Dr Ove Juul Nielsen; Rotherham District
General Hospital: Dr HF Barker, Dr P C Taylor; Royal Berkshire Hospital:
Dr G Morgenstern, Dr Rebecca Sampson; Royal Bournemouth General Hospital:
Dr S Killick; Royal Cornwall Hospital (Treliske): Dr A R Kruger, Dr Bryson
Pottinger, Dr E Parkins, Dr R Noble; Royal Devon & Exeter Hospital (Wonford):
Dr Anthony Todd, Dr Jackie Ruell, Dr M V Joyner, Dr Malcolm Hamilton, Dr R Lee;
Royal Free Hospital: Dr A Mehta, Dr Christopher McNamara, Dr P Kottaridis;
Royal Hallamshire Hospital: Dr C Dalley, Dr J Snowden, Professor JT Reilly; Royal
Stoke University Hospital (University Hospital of North Midlands NHS Trust):
Dr A Stewart; Royal Sussex County Hospital: Dr J Duncan, Dr Timothy Corbett;
Royal United Hospital Bath: Dr C R J Singer, Dr Chris Knechtli, Dr Josephine
Crowe, Dr Sarah Wexler; Russells Hall Hospital: Dr C Taylor, Dr D Bareford,
Dr J Neilson, Dr S Fernandes; Salford Royal Hospital: Dr JB Houghton, Dr Simon
Jowitt, Dr Sonya Ravenscroft; Salisbury District Hospital: Dr Efﬁe Grand,
Dr JO Cullis; Sandwell General Hospital: Dr John Gillson; Singleton Hospital:
Dr A Benton, Dr H Sati, Dr S Al-Ismail; Southampton General Hospital:
Dr D Richardson, Dr K Orchard; Southern General Hospital: Dr AE Morrison;
Southport & Formby District General Hospital: Dr Ruhaman Salim; St
Bartholomew's Hospital: Dr Heather Oakervee, Dr J Cavenagh, Dr Samir
Agrawal; St George's Hospital: Dr F Willis; St Helier Hospital: Dr J Mercieca,
Dr M Clarke, Dr R Zuha; St James's University Hospital: Dr BA Mcverry,
Dr DT Bowen, Dr GM Smith, Dr Rod Johnson; St Richard's Hospital: Dr Philip C
Bevan, Dr S Janes; Staffordshire General Hospital: Dr P Revell; Stirling Royal
Inﬁrmary: Dr RF Neilson; Stoke Mandeville Hospital: Dr H Eagleton; The Great
Western Hospital: Dr AG Gray, Dr Alex Sternberg, Dr ES Green, Dr NE Blesing;
The James Cook University Hospital: Dr Angela Wood, Dr D Plews, Dr R Dang;
The Royal Bolton Hospital: Dr J Jip; The Royal Liverpool University Hospital:
Dr RE Clark; The Royal Oldham Hospital: Dr Allameddine Allameddine,
Dr S Elhanash; The Royal Victoria Inﬁrmary: Dr Anne Lennard, Dr Gail Jones,
Dr Graham H Jackson; Torbay District General Hospital: Dr D Turner, Dr Nichola
Rymes, Dr P Roberts; Trafford General Hospital: Dr D Alderson; University
College Hospital: Dr A Khwaja, Dr K Ardeshna, Dr KG Patterson; University
Hospital Aintree: Dr A Olujohungbe, Dr BE Woodcock, Dr R Dasgupta,
Dr Ruhaman Salim, Dr W Sadik; University Hospital Coventry (Walsgrave):
Dr Anton G Borg, Dr B Harrison, Dr M Narayanan, Dr N Jackson, Dr Shailesh
Jobanputra; University Hospital Lewisham: Dr N Mir, Dr T Yeghen; University
Hospital Of North Tees: Dr P Mounter; University Hospital Of Wales:
Dr C Poynton, Dr C Rowntree, Dr Jonathan Kell, Dr S Knapper, Professor AK
Burnett; Victoria Hospital: Dr S Rogers; Victoria Inﬁrmary: Dr P Tansey,
Dr RA Sharp; Warwick Hospital: Dr Anton G Borg, Dr Peter E Rose; Western
General Hospital: Dr PH Roddie, Dr PRE Johnson; Wexham Park Hospital:
Dr N Bienz, Dr PH Mackie, Dr Simon Moule; Whiston Hospital: Dr G Satchi,
Dr JA Tappin, Dr Toby Nicholson; Wishaw General Hospital: Dr CL Thomas,
Dr Gilla Helenglass; Worcestershire Royal Hospital: Dr AH Sawers, Dr N
Pemberton, Dr S Shafeek; Worthing Hospital: Dr AM O'Driscoll;
Wycombe General Hospital: Dr J Pattinson, Dr R Aitchison; York Hospital:
Dr LR Bond, Dr MR Howard; Ysbyty Glan Clwyd: Dr C Hoyle,
Dr Earnest Heartin, Dr MJ Goodrick; Ysbyty Gwynedd District General Hospital:
Dr James Seale.
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